{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Botty van den Bruele A"],"funding":["National Cancer Institute","NCI NIH HHS"],"pagination":["307-315"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9448355"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["189(2)"],"pubmed_abstract":["<h4>Purpose</h4>HER2 +- amplified breast cancer patients derive benefit from treatment with anti-HER2-targeted therapy. Though adjuvant treatment is based on final pathology, decisions regarding neoadjuvant chemotherapy are made in the preoperative setting with imaging playing a key role in staging. We examined the accuracy of pre-operative imaging in determining pathological tumor size  (pT) in patients undergoing upfront surgery.<h4>Methods</h4>Early (cT1-T2N0) HER2 + breast cancer patients who underwent upfront surgery between 2015 and 2016 were identified from a prospective institutional database. We compared data for both clinical and final pathologic stage. Only those who underwent magnetic resonance imaging (MRI), mammography, and ultrasound in the preoperative setting were included"],"journal":["Breast cancer research and treatment"],"pubmed_title":["Does preoperative MRI accurately stratify early-stage HER2 + breast cancer patients to upfront surgery vs neoadjuvant chemotherapy?"],"pmcid":["PMC9448355"],"funding_grant_id":["P30 CA008748"],"pubmed_authors":["Hogan MP","Fornier MN","Botty van den Bruele A","Javed-Tayyab S","Morrow M","Le T","Sevilimedu V","Ferraro E","Sacchini V"],"additional_accession":[]},"is_claimable":false,"name":"Does preoperative MRI accurately stratify early-stage HER2 + breast cancer patients to upfront surgery vs neoadjuvant chemotherapy?","description":"<h4>Purpose</h4>HER2 +- amplified breast cancer patients derive benefit from treatment with anti-HER2-targeted therapy. Though adjuvant treatment is based on final pathology, decisions regarding neoadjuvant chemotherapy are made in the preoperative setting with imaging playing a key role in staging. We examined the accuracy of pre-operative imaging in determining pathological tumor size  (pT) in patients undergoing upfront surgery.<h4>Methods</h4>Early (cT1-T2N0) HER2 + breast cancer patients who underwent upfront surgery between 2015 and 2016 were identified from a prospective institutional database. We compared data for both clinical and final pathologic stage. Only those who underwent magnetic resonance imaging (MRI), mammography, and ultrasound in the preoperative setting were included","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Sep","modification":"2025-05-29T16:11:23.199Z","creation":"2025-04-06T01:48:26.535Z"},"accession":"S-EPMC9448355","cross_references":{"pubmed":["34263366"],"doi":["10.1007/s10549-021-06331-3"]}}